- Home
- APGE vs UTG Comparison
APGE vs UTG Comparison
Compare APGE & UTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- UTG
- Stock Information
- Founded
- APGE 2022
- UTG 2003
- Country
- APGE United States
- UTG United States
- Employees
- APGE N/A
- UTG N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- UTG Investment Managers
- Sector
- APGE Health Care
- UTG Finance
- Exchange
- APGE Nasdaq
- UTG Nasdaq
- Market Cap
- APGE 3.0B
- UTG 2.8B
- IPO Year
- APGE 2023
- UTG N/A
- Fundamental
- Price
- APGE $48.46
- UTG $31.73
- Analyst Decision
- APGE Strong Buy
- UTG
- Analyst Count
- APGE 6
- UTG 0
- Target Price
- APGE $75.40
- UTG N/A
- AVG Volume (30 Days)
- APGE 588.6K
- UTG 319.3K
- Earning Date
- APGE 11-12-2024
- UTG 01-01-0001
- Dividend Yield
- APGE N/A
- UTG 9.31%
- EPS Growth
- APGE N/A
- UTG N/A
- EPS
- APGE N/A
- UTG N/A
- Revenue
- APGE N/A
- UTG N/A
- Revenue This Year
- APGE N/A
- UTG N/A
- Revenue Next Year
- APGE N/A
- UTG N/A
- P/E Ratio
- APGE N/A
- UTG N/A
- Revenue Growth
- APGE N/A
- UTG N/A
- 52 Week Low
- APGE $22.20
- UTG $23.24
- 52 Week High
- APGE $72.29
- UTG $29.50
- Technical
- Relative Strength Index (RSI)
- APGE 47.85
- UTG 32.95
- Support Level
- APGE $41.85
- UTG $31.65
- Resistance Level
- APGE $48.27
- UTG $33.25
- Average True Range (ATR)
- APGE 3.56
- UTG 0.54
- MACD
- APGE 0.31
- UTG -0.34
- Stochastic Oscillator
- APGE 47.51
- UTG 6.59
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About UTG Reaves Utility Income Fund of Beneficial Interest
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.